Compare AbbVie Inc (ABBV) vs iShares MSCI Japan ETF (EWJ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares MSCI Japan ETF — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while iShares MSCI Japan ETF trades at $92.07. The key difference: AbbVie Inc pays a 2.72% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals.
| ABBV | EWJ | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $96.97 |
52-Week Low | $184.85 | $71.69 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
EWJ, the iShares MSCI Japan ETF, trades at $95.27, up 2.29% on the day, with a bullish technical signal driven by moving averages. The ETF provides exposure to Japanese equities, with recent news highlighting yen volatility and strong export data. Key support is at $94, with resistance at $96. A dividend of $0.50 is scheduled for June 2026.
Outlook remains tied to Japan's economic trends and currency dynamics. Opportunities include AI-driven export growth, but risks involve yen weakness and geopolitical tensions. Investors should weigh Japan's monetary policy shifts and global market sentiment for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →
